 |
24 Diseases |  |
12 Trials |
|
12 Trials |  |
871 News |  |
| «12345678910111213» |
- | Fycompa (perampanel) / Eisai, Briviact (brivaracetam) / UCB
Retrospective data, Journal, Real-world evidence: Comparison of the effectiveness and tolerability of perampanel and brivaracetam: a real-world, observational, retrospective study. (Pubmed Central) - Apr 7, 2021
Lastly, BRV was shown to be more effective in patients who were not previously treated with LEV. This retrospective study reveals comparable effectiveness and tolerability between PER and BRV also when used as first add-on treatments, in patients with epilepsy.
- || Briviact (brivaracetam) / UCB
Clinical, Journal, HEOR: Long-term safety, efficacy, and quality of life during adjunctive brivaracetam treatment in patients with uncontrolled epilepsy: An open-label follow-up trial. (Pubmed Central) - Mar 30, 2021
P3
In this select group of patients who entered the LTFU trial, BRV was generally safe and well tolerated. Results indicate the long-term efficacy of BRV in patients with focal seizures.
- ||| Briviact (brivaracetam) / UCB
Journal, Adverse events: Time course of drug-related treatment-emergent adverse side effects of brivaracetam. (Pubmed Central) - Mar 24, 2021
P3
Drug-related CNS TEAEs occurred early and substantially habituated over several weeks. TEAEs of ASMs might be better represented by division into early and late phases to guide clinician monitoring and patient expectations.
- Fycompa (perampanel) / Eisai, Briviact (brivaracetam) / UCB
[VIRTUAL] A systematic review of behavioral adverse events with brivaracetam, levetiracetam, perampanel, and topiramate in real-world studies () - Mar 18, 2021 - Abstract #AAN2021AAN_985;
Differences in methods, BAE definitions, and populations across studies make a conclusion difficult. However, switching from LEV to BRV appears to result in improvement of BAEs.
- Briviact (brivaracetam) / UCB
[VIRTUAL] Outcomes of Intravenous Use of Brivaracetam and Levetiracetam for the Treatment of Seizures in US Hospitals () - Mar 18, 2021 - Abstract #AAN2021AAN_897;
Use of intravenous BRV may provide an alternative to intravenous LEV for the management of seizures in the hospital setting due to lower prevalence of ICU admission, intubation, and 30-day seizure-related readmissions. Larger controlled studies are needed to confirm these preliminary findings.
- Vimpat (lacosamide) / UCB, Daiichi Sankyo, Briviact (brivaracetam) / UCB
[VIRTUAL] Intravenous Antiseizure Medication Utilization Patterns Among Seizure Patients Treated in US Hospitals: a Database Analysis () - Mar 18, 2021 - Abstract #AAN2021AAN_896;
A high percentage of patients receiving IV ASMs with no step-down to oral was observed, which may signal inappropriate post-discharge treatment. More research is needed to better understand why many IV ASMs were not stepped-down to an oral ASM prior to discharge.
- Xcopri (cenobamate) / SK Bio, Arvelle Therap
[VIRTUAL] Clinical Update For Cenobamate: Patients’ Experiences of Efficacy and Side Effects () - Mar 18, 2021 - Abstract #AAN2021AAN_878;
Adverse effects represent Cenobamate’s pharmacokinetic/pharmacodynamic interactions with other AEDs. To remedy this, it may be reasonable to proactively reduce doses of concurrent AEDs, when safe from clinical standpoint.
- Briviact (brivaracetam) / UCB
[VIRTUAL] Safety and Tolerability of Intravenous Brivaracetam in Patients with Epilepsy on Concomitant Levetiracetam Treatment () - Mar 18, 2021 - Abstract #AAN2021AAN_872;
P3
In patients taking concomitant LEV, IV BRV was generally well tolerated with a tolerability profile similar to the overall study population. Therefore, IV BRV may be considered a safe additional treatment option in patients with focal seizures unable to receive oral BRV.
- |||| brivaracetam / Generic mfg.
Enrollment open: A Study to Test the Safety and Tolerability of Brivaracetam in Children and Adolescents With Seizures (clinicaltrials.gov) - Mar 18, 2021
P3, N=100, Recruiting, Sponsor: UCB Biopharma SRL
Therefore, IV BRV may be considered a safe additional treatment option in patients with focal seizures unable to receive oral BRV. Not yet recruiting --> Recruiting
- ||| Briviact (brivaracetam) / UCB
Is IV brivaracetam a better alternative to levetiracetam. for status epilepticus? In this study doses >2 mg/kg were effective. I like the idea of BRV 300-400 mg as a loading dose, just like to 3-4 g loading dose for LVT. @drejgilmore ?? https://t.co/hqMQDlRjvo (Twitter) - Mar 17, 2021
- || Briviact (brivaracetam) / UCB
Clinical, Retrospective data, Journal: Α Multicenter Retrospective Study Evaluating Brivaracetam in the Treatment of Epilepsies in Clinical Practice. (Pubmed Central) - Mar 7, 2021
Twenty-six patients (17%) showed clinically significant adverse events, but none were life threatening. Brivaracetam seems to be an effective, easy to use and safe antiepileptic drug in the clinical setting.
- || Briviact (brivaracetam) / UCB
PK/PD data, Journal: Brivaracetam for the treatment of focal-onset seizures: pharmacokinetic and pharmacodynamic evaluations. (Pubmed Central) - Mar 5, 2021
Although BRV is not approved for the treatment of SE, it has demonstrated promising preliminary results. Further studies are needed to explore the efficacy and tolerability of BRV in SE.
- || Trileptal (oxcarbazepine) / Novartis
Clinical, Review, Journal: Anti-seizure medications and efficacy against focal to bilateral tonic-clonic seizures: A systematic review with relevance for SUDEP prevention. (Pubmed Central) - Mar 2, 2021
The ASMs that yielded the most data (3 or more studies) were topiramate (TPM), followed by tiagabine (TGB), brivaracetam (BRV), and lamotrigine (LTG)...Promising results, but with data from only one or two studies, were seen with cenobamate (18-59% efficacy above placebo), lacosamide (45.1-78.7%), levetiracetam (40.1-60.3%), oxcarbazepine (58.5-81.5%), and gabapentin (50-53.8%)...This review was our attempt at filling a gap in the literature and calling for universal reporting of data specific to BTC seizure reduction in all future studies, preferably including specific reporting on nocturnal BTCS. This will help enable rational ASM selection to minimize BTC seizures and thereby decrease the risk of SUDEP.
- | Briviact (brivaracetam) / UCB
Journal: Intravenous brivaracetam for the management of refractory focal non-convulsive status epilepticus. (Pubmed Central) - Feb 17, 2021
However, limited data exist on brivaracetam's efficacy in SE. We describe a patient case with focal NCSE refractory to levetiracetam, fosphenytoin, lacosamide and valproate who demonstrated clinical and electrographic improvement on continuous electroencephalography monitoring after brivaracetam administration.
- | pregabalin / Generic mfg.
Journal: Desymmetrization of Prochiral Cyclobutanones via Nitrogen Insertion: A Concise Route to Chiral γ-Lactams. (Pubmed Central) - Feb 5, 2021
In combination with an easy deprotection protocol, this operationally simple sequence allows the synthesis of a range of optically pure γ -lactams, including those bearing all-carbon quaternary stereo-centers. In addition, the formal synthesis of drug molecules baclofen, brivaracetam, and pregabalin further demonstrates the synthetic utility and highlights the general applicability of the presented method.
- || Briviact (brivaracetam) / UCB
Clinical, Journal: Randomized open-label trial of intravenous brivaracetam versus lorazepam for acute treatment of increased seizure activity. (Pubmed Central) - Feb 2, 2021
P2
Treatment-emergent adverse events were as expected for each medication. Although this trial should be interpreted with caution because of small patient numbers, it suggests a possible role of BRV in the acute treatment of increased seizure activity.
- || Briviact (brivaracetam) / UCB
Clinical, Journal: Adjunctive brivaracetam - A prospective audit of outcomes from an epilepsy clinic. (Pubmed Central) - Feb 2, 2021
The ASM can produce positive outcomes in patients who have failed LEV. Post-marketing studies remain a useful tool to evaluate the efficacy and tolerability of novel ASMs in everyday clinical practice.
- |||| brivaracetam / Generic mfg.
Trial completion date, Trial initiation date, Trial primary completion date, Monotherapy: EXPAND: A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy (clinicaltrials.gov) - Feb 2, 2021
P2/3, N=160, Not yet recruiting, Sponsor: UCB Biopharma SRL
Post-marketing studies remain a useful tool to evaluate the efficacy and tolerability of novel ASMs in everyday clinical practice. Trial completion date: Dec 2023 --> Apr 2024 | Initiation date: Dec 2020 --> Apr 2021 | Trial primary completion date: Nov 2023 --> Apr 2024
- | Briviact (brivaracetam) / UCB
Retrospective data, Journal: Brivaracetam efficacy and tolerability in clinical practice: A UK-based retrospective multicenter service evaluation. (Pubmed Central) - Jan 21, 2021
This 'real-life' evaluation suggests that reductions in seizure frequency can be achieved with BRV in patients with highly refractory epilepsy. Brivaracetam may be a useful treatment option in patients who have previously failed to respond to or tolerate LEV, those with LD, or (off-label) those with generalized epilepsies.
- || Briviact (brivaracetam) / UCB
Clinical, Journal: Clinical experience with brivaracetam in a series of 46 children. (Pubmed Central) - Jan 21, 2021
Brivaracetam is effective in very diverse childhood epilepsies, including some that present with primarily generalized seizures. Given the characteristics of the population studied, we have not been able to confirm a better tolerability of BRV compared with levetiracetam (LEV).
- |||||||| brivaracetam / Generic mfg.
New P3 trial: A Study to Test the Safety and Tolerability of Brivaracetam in Children and Adolescents With Seizures (clinicaltrials.gov) - Jan 19, 2021
P3, N=100, Not yet recruiting, Sponsor: UCB Biopharma SRL
- | Briviact (brivaracetam) / UCB
Journal: Intravenous brivaracetam and lorazepam for acute seizure control: Are they equally effective? (Pubmed Central) - Jan 16, 2021
Given the characteristics of the population studied, we have not been able to confirm a better tolerability of BRV compared with levetiracetam (LEV). No abstract available
- | Briviact (brivaracetam) / UCB
Journal: Response to Letter to the Editor "Intravenous brivaracetam and lorazepam for acute seizure control: Are they equally effective?" (Pubmed Central) - Jan 16, 2021
No abstract available No abstract available
- Briviact (brivaracetam) / UCB
[VIRTUAL] Current use strategies of pyrrolidine antiseizure medications levetiracetam and brivaracetam in adult and pediatric patients in the inpatient hospital setting () - Dec 26, 2020 - Abstract #ASHP2020ASHP_3741;
Descriptive statistics will be utilized to summarize collected data. Results will include off-label use based on indication, age, organ function and/or total dose, quantity and duration of IV utilization, cost comparison of IV vs PO formulations, and percentage of improperly timed levetiracetam drug levels.
- Briviact (brivaracetam) / UCB
[VIRTUAL] Brivaracetam initiation at a four-hospital community health system () - Dec 26, 2020 - Abstract #ASHP2020ASHP_1814;
The secondary objective is to evaluate the following: percentage of oral brivaracetam orders with FDA approved doses, percentage of intravenous orders inappropriately prescribed for patients under age of sixteen, and the percentage of brivaracetam orders prescribed by authorized providers. Descriptive statistics will be used for the analysis.
- || Briviact (brivaracetam) / UCB
Clinical, Journal, Real-world evidence: Brivaracetam as add-on treatment in focal epilepsy: A real-world time-based analysis. (Pubmed Central) - Dec 17, 2020
Add-on BRV improved seizure control in LEV-naive and LEV-prior patients. The time-to-baseline seizure count represents an informative endpoint alongside traditional study outcomes and designs.
- | Briviact (brivaracetam) / UCB
Journal: Brivaracetam-A good alternative for the treatment of muscle cramps (Pubmed Central) - Dec 16, 2020
The time-to-baseline seizure count represents an informative endpoint alongside traditional study outcomes and designs. Further studies are needed to demonstrate the effect of brivaracetam on muscle cramps.
- |||||||| brivaracetam / Generic mfg.
New P2/3 trial, Monotherapy: EXPAND: A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy (clinicaltrials.gov) - Dec 13, 2020
P2/3, N=160, Not yet recruiting, Sponsor: UCB Biopharma SRL
- || Briviact (brivaracetam) / UCB, Trileptal (oxcarbazepine) / Novartis
Clinical, Journal: Influence of dose and antiepileptic comedication on brivaracetam serum concentrations in patients with epilepsy. (Pubmed Central) - Dec 1, 2020
Our results from routine therapeutic drug monitoring data indicate that the effect of enzyme-inducing AEDs on BRV serum concentrations is stronger than the 20%-30% reduction in BRV exposure previously reported in pharmacokinetics studies. Further research is necessary to evaluate these differences and to elucidate possible clinical consequences.
- Briviact (brivaracetam) / UCB
[VIRTUAL] Long-term retention, efficacy and tolerability of adjunctive brivaracetam by number of lifetime antiepileptic drugs in adults with focal seizures: a post hoc analysis () - Nov 28, 2020 - Abstract #AES2020AES_1273;
P3
Long-term efficacy was highest in patients with 1-2 lifetime AEDs and decreased by number of lifetime AEDs, though patients exposed to ≥7 AEDs could also benefit from long-term BRV treatment. Efficacy of adjunctive BRV was sustained over time independent of number of lifetime AEDs.
- Briviact (brivaracetam) / UCB
[VIRTUAL] Pathogenic Variant in GABRA1 Linked to Epileptic Encephalopathy with Focal Seizure Onset from the Occipital Lobe () - Nov 28, 2020 - Abstract #AES2020AES_1165;
Diaphragm myoclonic seizures may be misdiagnosed as vocal tics. Intellectual disability is common but comorbidity with obsessive-compulsive disorder and infantile autism is also possible.
- Briviact (brivaracetam) / UCB
[VIRTUAL] Effectiveness and quality of life during 12-month adjunctive brivaracetam treatment in a real-life setting: interim data from a prospective observational study in Europe () - Nov 28, 2020 - Abstract #AES2020AES_1042;
P=N/A
Observed results for QoL improved over time, possibly due to patients with poor response discontinuing. A numerically higher proportion of patients had improvement than worsening in QOLIE-31-P total score and individual subdomains.
- Briviact (brivaracetam) / UCB, Aptiom (eslicarbazepine) / Sumitomo Dainippon, Eisai
[VIRTUAL] Network Meta-analysis Comparing the Psychiatric Treatment-emergent Adverse Events of Eslicarbazepine Acetate and Brivaracetam () - Nov 28, 2020 - Abstract #AES2020AES_968;
Using the NMA technique described, ESL was associated with a profile suggesting a lesser likelihood of psychiatric TEAEs, relative to BRV; however, these differences were not statistically significant. Funding: Sunovion Pharmaceuticals Inc.
- Fycompa (perampanel) / Eisai
[VIRTUAL] Perampanel for the Treatment of Epilepsy in a Patient with Generalized Tonic-Clonic Seizures and Myoclonic Jerks () - Nov 28, 2020 - Abstract #AES2020AES_946;
GTC seizure freedom has been sustained since March 2019 in this adult male patient on perampanel monotherapy (6 mg/day), with no adverse events reported. Funding: Medical writing support, under the direction of Dr Holtzman, was provided by Rebecca Furmston, PhD, of CMC AFFINITY, McCann Health Medical Communications, funded by Eisai Inc., in accordance with Good Publication Practice guidelines.
- Briviact (brivaracetam) / UCB
[VIRTUAL] 12-month effectiveness and tolerability of brivaracetam in the real world: the international, non-interventional EXPERIENCE study () - Nov 28, 2020 - Abstract #AES2020AES_912;
The results will be more informative about BRV effectiveness and tolerability than results from clinical trials, and will provide additional outcomes for key patient subgroups that are often excluded from clinical trials. Of note, this is the first study with the statistical power to assess patient subgroups across a wide geography, to produce the first RWE BRV findings for each key subgroup and help identify which subgroup may benefit the most from BRV.
- Briviact (brivaracetam) / UCB
[VIRTUAL] Brivaracetam: Long term experience in Mexico () - Nov 28, 2020 - Abstract #AES2020AES_905;
B: Patients on levetiracetam (LVT) treatment and switched to brivaracetam due to undesirable adverse events...The most common and useful combination was with lacosamide...The primary adverse effect was a long-lasting drowsy-lethargic state, which impeded patients' daily activities. Funding: No funding was required for this study
- ceftriaxone / Generic mfg., ziprasidone / Generic mfg.
[VIRTUAL] Nonconvulsive Status Epilepticus as the Presenting Symptoms of Neuroleptic Malignant Syndrome () - Nov 28, 2020 - Abstract #AES2020AES_678;
It can occur even after several years on the same regimen. NMS can present with new onset seizure.
- Briviact (brivaracetam) / UCB
[VIRTUAL] Cumulative Plasma Exposure, Not Singular Concentrations, Yields a Best Correlation for Brivaracetam, Levetiracetam to Photoparoxysmal Abolition in Photosensitive Epilepsy: Results of Randomized, Double-blind, Crossover Study () - Nov 28, 2020 - Abstract #AES2020AES_638;
P2/3
Singular Ln plasma concentrations do not correlate well. Frequent plasma samples are needed when evaluating novel AED compounds in the ‘Photosensitivity Model of Epilepsy’ to calculate cumulative [AED] exposure.
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
[VIRTUAL] Electroconvulsive therapy as a last resort for suprarefractory status epilepticus in a patient with severe NMDA-R-Ab autoimmune encephalitis and decompression hemicraniectomy () - Nov 28, 2020 - Abstract #DGN2020DGN_513;
Even if there are indications from case series of a possible effectiveness of ECT in SRSE, there is no evidence both prospective data on the effectiveness of ECT in SRSE and clear recommendations on therapy escalation beyond the use of general anesthetics. The use of an ECT in hemicraniectomized patients, as in our case, is because of the changed Anatomy poses a particular challenge and has not yet been described in the literature; from our point of view can In individual cases, ECT may be helpful for SRSE despite hemicraniectomy.
- | Briviact (brivaracetam) / UCB
Retrospective data, Journal: Safety and tolerability of adjunctive brivaracetam in epilepsy: In-depth pooled analysis. (Pubmed Central) - Nov 19, 2020
P1, P2, P3
The use of an ECT in hemicraniectomized patients, as in our case, is because of the changed Anatomy poses a particular challenge and has not yet been described in the literature; from our point of view can In individual cases, ECT may be helpful for SRSE despite hemicraniectomy. These safety data for adjunctive BRV support its acceptable safety and tolerability profile.
- || brivaracetam / Generic mfg.
Trial completion: A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Intravenous Brivaracetam in Subjects >= 1 Month to < 16 Years of Age With Epilepsy (clinicaltrials.gov) - Nov 17, 2020
P2, N=50, Completed, Sponsor: UCB Biopharma S.P.R.L.
These safety data for adjunctive BRV support its acceptable safety and tolerability profile. Active, not recruiting --> Completed
- | brivaracetam / Generic mfg.
Trial initiation date: Brivaracetam to Reduce Neuropathic Pain in Chronic Spinal Cord Injury (clinicaltrials.gov) - Nov 15, 2020
P1/2, N=20, Not yet recruiting, Sponsor: University of Minnesota
Active, not recruiting --> Completed Initiation date: Sep 2020 --> Feb 2021
- || Briviact (brivaracetam) / UCB
P4 data, Retrospective data, Journal: First clinical postmarketing experiences in the treatment of epilepsies with brivaracetam: a retrospective observational multicentre study. (Pubmed Central) - Nov 12, 2020
The present study shows that results of the phase III studies on BRV match data from real life clinical settings. Brivaracetam seems to be a useful alternative in patients who have suffered adverse effects while taking LEV.
- || Briviact (brivaracetam) / UCB
Clinical, Journal: Efficacy, retention, and safety of brivaracetam in adult patients with genetic generalized epilepsy. (Pubmed Central) - Nov 12, 2020
Brivaracetam shows good responder and retention rates in GGE and is generally well tolerated. It is an appropriate alternative treatment for GGE, especially in refractory epilepsy and when other AEDs are not tolerated.
- || Briviact (brivaracetam) / UCB
Clinical, Journal: Epileptic aura continua: A case report with response to brivaracetam. (Pubmed Central) - Nov 11, 2020
It is an appropriate alternative treatment for GGE, especially in refractory epilepsy and when other AEDs are not tolerated. No abstract available
- |||| brivaracetam / Generic mfg.
Trial completion date, Trial primary completion date: Open-label Long-term Study of Adjunctive Brivaracetam in Pediatric Subjects With Epilepsy (clinicaltrials.gov) - Oct 30, 2020
P3, N=600, Enrolling by invitation, Sponsor: UCB Pharma SA
No abstract available Trial completion date: Jun 2021 --> Jan 2022 | Trial primary completion date: Jun 2021 --> Jan 2022
- | brivaracetam / Generic mfg.
Enrollment closed: A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Intravenous Brivaracetam in Subjects >= 1 Month to < 16 Years of Age With Epilepsy (clinicaltrials.gov) - Oct 30, 2020
P2, N=48, Active, not recruiting, Sponsor: UCB Biopharma S.P.R.L.
Trial completion date: Jun 2021 --> Jan 2022 | Trial primary completion date: Jun 2021 --> Jan 2022 Recruiting --> Active, not recruiting
- || Briviact (brivaracetam) / UCB
Clinical, Journal: Time course of 75%-100% efficacy response of adjunctive brivaracetam. (Pubmed Central) - Oct 28, 2020
Recruiting --> Active, not recruiting The majority of patients achieving 75%-100% sustained seizure frequency reduction (all focal seizure types and the subpopulation with FBTCS) with oral BRV (100 or 200 mg/d) achieved this response on the first-treatment day.
- | Journal: Repurposed molecules for antiepileptogenesis: Missing an opportunity to prevent epilepsy? (Pubmed Central) - Oct 24, 2020
In addition, there are preclinical antiepileptogenic data for anakinra, rapamycin, fingolimod, and erythropoietin, although these medications have potential for more serious side effects...Here, we review animal and human antiepileptogenic evidence for these medications. We highlight the gaps in our knowledge for each molecule that need to be filled in order to consider clinical translation, and we suggest a platform of preclinical antiepileptogenesis evaluation of potentially repurposable molecules or their combinations going forward.
- | Briviact (brivaracetam) / UCB
Retrospective data, Journal: Comparison of the safety of brivaracetam at various doses among patients with epilepsy: A network meta-analysis of randomized controlled trials. (Pubmed Central) - Oct 23, 2020
In conclusion, BRV treatment at a dose of 50 mg/day may increase the risk of nervous system diseases and psychosis disorders compared with the placebo group. However, more high-quality clinical studies are warranted to validate these results.